All In Biotech

Drug Trial Radar · NCT06041438

A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the Blood

Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1584862 in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Design Study)

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

14

Actual

Start

Sep 29, 2023

Primary completion

Nov 10, 2023

Study completion Nov 10, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this trial is to investigate the effect on the exposure of BI 1584862 in plasma when given as single dose together with multiple doses of itraconazole (Test, T) as compared to BI 1584862 when given alone as oral single dose (Reference, R).

Conditions

  • Healthy

Interventions

  • BI 1584862Drug

    One dose with 240 mL of water after an overnight fast of at least 10 h

  • ItraconazoleDrug

    200 mg daily after an overnight fast of at least 9 h for several consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)Time frame: Within 3 to 4 h before and up to 3 days after BI 1584862 administration.
  2. Maximum Measured Concentration of BI 1584862 in Plasma (Cmax)Time frame: Within 3 to 4 h before and up to 3 days after BI 1584862 administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Humanpharmakologisches Zentrum Biberach

    Biberach, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.